Dr. Lillian Siu is a senior medical oncologist at the Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto. She is the Co-Principal Investigator of the Ontario Institute for Cancer Research-supported Ontario-wide Cancer Targeted Nucleic Acid Evaluation (OCTANE) study. Dr. Siu is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at the Princess Margaret Cancer Centre and holds the BMO Chair in Precision Cancer Genomics. She is the clinical lead for the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre, where she has been leading genomics initiatives and immuno-oncology trials. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016), as a member of the Nomination Committee for the American Association of Cancer Research (AACR, 2014-2016), and on the AACR Board of Directors for a three-year term (2017-2020).